Hideki Sakamoto
About Hideki Sakamoto
Hideki Sakamoto serves as the Executive Director and Head of Clinical Development & Medical Affairs for Insmed Incorporated in Japan. With extensive experience in the pharmaceutical industry, he has held various leadership roles at companies such as Eli Lilly, GSK, and MSD, focusing on research, development, and strategic partnerships.
Work at Insmed
Hideki Sakamoto serves as the Executive Director, Head of Clinical Development & Medical Affairs for Insmed Incorporated in Japan. He has held this position since 2021, overseeing the clinical development and medical affairs functions within the region. His role includes managing research initiatives and ensuring alignment with corporate objectives in the pharmaceutical landscape.
Current Role at SyntheticGestalt
Since 2020, Hideki Sakamoto has been an AI Drug Discovery Strategy Advisor at SyntheticGestalt. In this capacity, he contributes to the development of strategies that integrate artificial intelligence into drug discovery processes, leveraging his extensive experience in clinical development and medical affairs.
Previous Experience at Eli Lilly and Company
Hideki Sakamoto has a significant history with Eli Lilly and Company, where he worked in various roles from 1998 to 2009. His positions included Project Leader in neuroscience and oncology, Portfolio Management in Discovery Research, and Head of Scientific Licensing and Alliance Management. This experience provided him with a strong foundation in drug development and corporate strategy.
Experience at MSD and GSK
Sakamoto held the position of Head of Oncology Scientific Affairs at MSD from 2017 to 2021. Prior to that, he worked at GSK from 2010 to 2017, where he was Head of Corporate & Business Development and later in Medical Affairs. His roles at these organizations focused on advancing scientific initiatives and managing strategic partnerships.
Education and Expertise
Hideki Sakamoto earned his PhD and MS from Oregon Health and Science University, completing his studies from 1988 to 1994. His academic background supports his expertise in clinical development and medical affairs, contributing to his leadership roles in the pharmaceutical industry.